Biocon announced its inclusion in S&P’s Sustainability Yearbook 2024 for the second consecutive year, based on the S&P Global Corporate Sustainability Assessment (CSA) of Biocon and Biocon Biologics for 2023.
Biocon’s S&P Global ESG score was 63 versus 52 previously, placing it among the Top 10 global biotech companies from within the 300 companies that were assessed.
The S&P Global CSA, a leading corporate sustainability database, enables companies to directly report key sustainability metrics and benchmark their sustainability performance on a wide range of industry-specific economic, environmental, and social criteria. The CSA score shows how a company compares with its peers and members of the prestigious Dow Jones Sustainability Indices (DJSI).
Based on its score, Biocon (including Biocon Biologics) has also been named among global sustainability leaders for the third consecutive year in the Dow Jones Sustainability Emerging Markets Index. This index tracks the performance of the top 10 per cent of the 800 largest Emerging Markets companies in the S&P Global Broad Market Index leading the field in terms of sustainability. It is one among the two pharma biotech companies from India on the index.
Key highlights of Biocon (including Biocon Biologics) 2023 S&P Global ESG scores:
• Environmental Dimension: Achieved a score of 69, the industry mean is 12.
• Social Dimension: Achieved a score of 62, the industry mean is 24.
• Governance & Economic Dimension: Achieved a score of 62, the mean is 30